highthroughput
screen
ht
larg
compound
librari
becom
commonli
use
method
identif
drug
lead
nonphysiolog
reduc
agent
wide
use
ht
howev
comparison
differ
ht
result
base
choic
reduc
agent
use
potenc
comparison
select
inhibitor
done
physiolog
reduc
agent
reduc
glutathion
gsh
compar
effect
three
reduc
agentsdithiothreitol
dtt
bmercaptoethanol
bmce
tri
phosphin
tcep
well
gsh
three
drug
target
protein
approxim
compound
comput
screen
target
protein
experiment
test
highscor
compound
compound
four
reduc
agent
surprisingli
produc
mani
nonoverlap
hit
importantli
found
variou
reduc
agent
alter
inhibitor
potenc
ic
approxim
lm
one
reduc
agent
complet
loss
ic
lm
inhibitori
activ
anoth
reduc
agent
therefor
choic
reduc
agent
ht
critic
may
lead
pursuit
fals
identifi
activ
compound
failur
identifi
true
activ
compound
demonstr
feasibl
use
gsh
vitro
ht
assay
three
target
enzym
highthroughput
screen
ht
larg
compound
librari
becom
wide
use
identif
drug
lead
perform
ht
expens
timeconsum
henc
strict
qualiti
control
essenti
elimin
compound
caus
protein
aggreg
gener
fals
posit
hit
deterg
triton
tween
chap
ad
assay
buffer
carrier
protein
bovin
serum
albumin
bsa
also
ad
decreas
enzym
loss
pipett
surfac
well
stabil
target
enzym
reaction
addit
reduc
agent
assay
import
prevent
oxid
cystein
target
protein
avoid
select
compound
coval
interact
cystein
three
reduc
agent
commonli
use
ht
assay
dithiothreitol
dtt
bmercaptoethanol
bmce
tri
phosphin
tcep
studi
shown
strong
reduc
agent
dtt
tcep
gener
h
chain
reaction
oxidationreduct
redox
cycl
presenc
redox
cycl
compound
rcc
lead
fals
posit
case
weaker
reduc
agent
reduc
glutathion
gsh
bmce
cystein
extens
studi
done
reduc
fals
posit
presenc
strong
reduc
agent
howev
studi
perform
investig
reduct
fals
neg
reduc
agent
select
studi
done
yet
compar
differ
outcom
ht
potenc
ic
valu
select
compound
variou
reduc
agent
compar
physiolog
reduc
agent
gsh
therefor
examin
effect
reduc
agent
dtt
bmce
tcep
well
physiolog
reduc
agent
gsh
three
drug
target
protein
human
sarscov
proteas
papainlik
proteas
plpro
hepat
c
viru
hcv
plpro
cystein
proteas
wherea
serin
proteas
wide
shallow
activ
site
activ
site
pocket
open
wherea
plpro
rel
constrict
caus
differ
characterist
addit
divers
system
test
effect
reduc
agent
compound
screen
assay
proteas
attract
target
new
antivir
drug
design
due
crucial
role
viral
replic
process
hcv
major
caus
chronic
liver
diseas
affect
million
peopl
world
popul
human
sarscov
respons
largescal
epidem
differ
countri
five
contin
see
front
matter
elsevi
inc
right
reserv
death
work
goal
ensur
qualiti
screen
campaign
test
effect
differ
reduc
agent
assay
result
avoid
fals
posit
fals
neg
enzym
assay
perform
three
proteas
approxim
comput
prescreen
compound
librari
compound
virtual
screen
target
perform
five
parallel
assay
one
four
reduc
agent
one
reduc
agent
present
effect
reduc
agent
primari
screen
result
potenc
screen
inhibitor
plasmid
construct
purif
hcv
sarscov
plpro
gene
fulllength
hcv
hcv
polyprotein
residu
histag
n
terminu
residu
codon
optim
synthes
biobas
clone
vector
coexpress
rosetta
cell
novagen
contain
recombin
plasmid
grown
luriabertani
lb
medium
overexpress
togeth
mm
isopropyl
iptg
h
harvest
cell
lyse
sonic
lysi
buffer
mgml
lysozym
proteas
inhibitor
cocktail
buffer
mm
hepe
ph
mm
nacl
mm
imidazol
mm
bmce
triton
glycerol
histag
fuse
purifi
histrap
hp
column
ge
healthcar
gradient
buffer
b
mm
hepe
ph
mm
nacl
mm
imidazol
mm
bmce
triton
glycerol
follow
size
exclus
column
chromatographi
purif
buffer
c
mm
hepe
ph
mm
nacl
mm
dtt
triton
glycerol
sarscov
polyprotein
residu
plpro
residu
gene
prepar
codonoptim
gene
synthesi
clone
vector
respect
overexpress
purif
plpro
similar
minor
adjust
buffer
compon
step
protein
vernali
leadlik
librari
compound
zinc
databas
version
screen
use
multistep
screen
protocol
select
compound
purchas
enzymat
assaybas
test
inhibitori
activ
papainlik
proteas
sarscov
dynam
pharmacophor
model
develop
base
multipl
protein
structur
ensembl
extract
extend
molecular
dynam
simul
plpro
enzym
compound
screen
use
pharmacophor
model
follow
second
filter
step
flexibl
dock
use
gold
version
cluster
use
moe
macc
perform
topscor
compound
previou
two
screen
step
select
compound
purchas
compound
screen
inhibit
proteas
hcv
clean
leadlik
subset
zinc
databas
version
multiti
dock
protocol
use
surflexdock
ehit
progress
use
screen
librari
choos
compound
purchas
test
detail
publish
elsewher
vernali
leadlik
clean
leadlik
subset
zinc
databas
version
screen
priorit
compound
experiment
test
enzym
screen
protocol
employ
tier
dock
consensu
score
along
dynam
pharmacophorebas
screen
tier
dock
protocol
involv
dock
surflexdock
follow
cluster
gener
repres
set
divers
compound
repres
set
redock
gold
follow
rescor
use
amberdock
final
compound
rank
use
ranksum
consensu
method
pregener
conform
molecul
repres
set
compar
pharmacophor
model
gener
use
comput
solvent
map
csm
topscor
commerci
avail
compound
pharmacophor
hit
visual
inspect
elimin
reactiv
compound
effici
span
bind
site
final
compound
order
experiment
assay
activ
complex
sarscov
measur
continu
kinet
assay
fluoresc
reson
energi
transfer
fret
base
substrat
acdedap
eeabuw
coo
asc
nh
nh
respect
anaspec
substrat
gener
fluoresc
signal
excit
k
nm
emiss
k
nm
quencher
cleav
respect
proteas
plpro
activ
also
measur
continu
kinet
assay
ubiquitinderiv
substrat
zargleuargglyglyamc
bachem
bioscienc
gener
fluoresc
signal
excit
k
nm
emiss
k
nm
aminomethyl
coumarin
amc
cleav
hcv
assay
perform
assay
buffer
contain
mm
tri
ph
chap
glycerol
mgml
bsa
seri
substrat
concentr
lm
prepar
triplic
enzym
reaction
initi
ad
hcv
nm
final
concentr
seri
substrat
concentr
without
enzym
also
measur
control
two
sarscov
proteas
nm
plpro
nm
analyz
buffer
contain
mm
hepe
ph
triton
mgml
bsa
seri
differ
substrat
concentr
mm
plpro
lm
fluoresc
intens
monitor
continu
min
polarstar
optima
micropl
reader
bmg
labtech
three
proteas
assay
perform
final
assay
volum
lowvolum
micropl
corn
mm
reduc
agent
ad
assay
buffer
except
control
set
micha
constant
k
maxim
activ
v
max
calcul
fit
data
hyperbol
equat
initi
veloc
x
concentr
substrat
initi
inhibitor
screen
mm
stock
solut
compound
chembridg
asinex
bioscreen
chemdiv
life
chemic
enamin
prepar
dimethyl
sulfoxid
dmso
dilut
final
concentr
assay
buffer
mm
hepe
ph
triton
mgml
bsa
dmso
plpro
incub
nm
plpro
respect
min
reaction
initi
ad
substrat
concentr
lm
lm
lm
plpro
monitor
fluoresc
intens
polarstar
optima
micropl
reader
bmg
labtech
hcv
screen
done
similarli
differ
assay
buffer
mm
tri
ph
chap
mgml
bsa
concentr
compound
test
duplic
plate
contain
total
posit
neg
control
ic
valu
measur
concentr
enzym
substrat
initi
screen
seri
compound
concentr
lm
assay
buffer
contain
dmso
improv
compound
solubl
enzym
reaction
initi
ad
fluorogen
substrat
activ
continu
monitor
least
min
ic
valu
calcul
fit
threeparamet
hill
equat
x
inhibitor
concentr
n
slope
concentrationrespons
curv
hill
slope
maxim
inhibit
three
independ
assay
amount
gsh
glutathion
disulfid
gssg
assay
buffer
measur
commerci
glutathion
assay
kit
biovis
per
assay
instruct
assay
kit
contain
ophthalaldehyd
opa
react
gsh
gssg
gener
fluoresc
excitationemiss
nm
assay
buffer
prepar
final
assay
volum
mm
gsh
absenc
gsh
control
assay
buffer
compon
indic
assay
anoth
set
assay
buffer
proteas
also
prepar
comparison
opa
ad
detect
gsh
amount
sampl
incub
min
room
temperatur
gsh
concentr
measur
fluoresc
intens
detect
polarstar
optima
micropl
reader
bmg
labtech
gssg
amount
detect
gsh
quench
first
ad
gsh
quencher
assay
kit
min
gssg
reduc
reduc
agent
mix
follow
addit
opa
detect
gsh
actual
gssg
amount
sampl
kept
room
temperatur
open
lid
allow
exposur
air
order
mimic
usual
ht
assay
condit
gsh
gssg
amount
monitor
time
period
approxim
compound
vernali
leadlik
librari
clean
leadlik
subset
zinc
databas
version
screen
use
multistep
screen
protocol
dynam
pharmacophor
model
develop
base
multipl
protein
structur
ensembl
pharmacophor
model
target
use
first
pass
screen
tool
compound
follow
second
filter
step
multiti
dock
perform
use
variou
program
includ
gold
version
surflexdock
andor
ehit
detail
publish
elsewher
total
highscor
compound
purchas
plpro
respect
use
correct
concentr
substrat
import
identifi
inhibitor
differ
mode
inhibit
substrat
concentr
high
much
higher
micha
constant
k
competit
inhibitor
might
detect
fals
neg
substrat
concentr
low
much
lower
k
uncompetit
inhibitor
miss
determin
k
maximum
activ
v
max
plpro
four
reduc
agent
dtt
tcep
gsh
bmce
without
reduc
agent
control
tabl
two
dtt
tcep
strong
reduc
agent
two
gsh
bmce
weaker
one
case
found
differ
reduc
agent
affect
v
max
differ
degre
rang
rel
v
max
reduc
agent
wherea
k
affect
although
tcep
dtt
classifi
strong
reduc
agent
tcep
decreas
enzym
effici
k
cat
k
half
wherea
dtt
increas
k
similar
four
reduc
agent
v
max
slightli
increas
four
reduc
agent
contrast
k
plpro
affect
differ
degre
depend
reduc
agent
use
k
plpro
increas
presenc
dtt
gsh
tcep
respect
compar
k
without
reduc
agent
tabl
demonstr
reduc
agent
significantli
affect
enzym
kinet
constant
differ
degre
differ
enzym
system
effect
need
taken
consider
design
ht
assay
initi
compound
screen
three
target
protein
perform
total
approxim
purchas
compound
absenc
reduc
agent
four
reduc
agent
present
assay
enzym
activ
also
analyz
seri
reduc
agent
concentr
rang
mm
see
fig
supplementari
materi
initi
screen
assay
done
duplic
plate
replic
plot
z
factor
shown
fig
z
factor
calcul
mean
standard
deviat
posit
neg
control
plate
z
factor
plpro
rang
respect
better
z
factor
rang
hcv
duplic
reproduc
total
test
compound
agre
within
plpro
respect
compound
show
inhibit
lm
concentr
consid
posit
hit
posit
tabl
surprisingli
mani
nonoverlap
posit
hit
compound
identifi
reduc
agent
three
proteas
clearli
indic
reduc
agent
significantli
affect
ht
assay
outcom
initi
screen
process
number
posit
presenc
either
dtt
bmce
smaller
presenc
gsh
wherea
tcep
select
posit
case
plpro
hand
bmce
detect
highest
number
posit
wherea
dtt
tcep
select
fewer
posit
gsh
screen
defin
true
posit
one
gsh
gsh
primari
intracellular
physiolog
reduc
agent
human
cell
three
target
enzym
function
goal
compound
screen
identifi
inhibitor
viral
enzym
develop
antivir
thu
identifi
inhibitor
activ
human
cell
gsh
present
high
concentr
logic
addit
may
good
test
inhibitori
activ
hit
compound
gssg
predomin
serum
compound
like
pass
human
serum
reach
intracellular
environ
base
definit
true
posit
found
tcep
produc
largest
number
fals
posit
case
fals
posit
identifi
absenc
reduc
agent
two
cystein
proteas
plpro
indic
necess
use
reduc
agent
two
enzym
tabl
see
also
tabl
supplementari
materi
dtt
show
largest
number
fals
neg
compound
identifi
posit
gsh
tcep
show
smallest
number
although
strong
reduc
compound
inhibit
lm
concentr
compound
consid
posit
hit
compound
shown
red
rectangl
agent
two
strong
reduc
agent
show
fals
neg
hand
dtt
show
compound
fals
neg
plpro
wherea
tcep
strong
reduc
agent
show
fals
neg
also
analyz
data
inhibit
cutoff
compar
cutoff
posit
hit
overal
result
came
similar
although
number
hit
obvious
smaller
cutoff
dtt
still
show
fals
neg
three
proteas
tcep
show
least
plpro
number
fals
neg
tcep
bmce
significantli
reduc
plpro
cutoff
case
three
reduc
agent
fals
posit
fals
neg
number
slightli
less
cutoff
investig
reduc
agent
effect
potenc
screen
compound
ic
valu
compar
reduc
agent
studi
surprisingli
ic
valu
posit
hit
three
target
significantli
affect
type
reduc
agent
fig
case
ic
valu
compound
significantli
affect
show
loss
inhibitori
activ
compound
presenc
dtt
andor
bmce
inhibitor
fig
inhibitor
tabl
fig
exhibit
loss
inhibitori
activ
presenc
either
dtt
tcep
even
without
reduc
agent
plpro
inhibitor
inhibitor
fig
also
detect
presenc
either
dtt
bmce
dtt
seem
produc
fals
neg
three
proteas
screen
compar
averag
hill
slope
valu
compound
display
dramat
shift
ic
valu
presenc
dtt
determin
whether
dtt
prevent
inhibit
assay
elimin
aggregationbas
inhibit
averag
hill
slope
valu
compound
compound
near
three
reduc
agent
except
compound
compound
hill
slope
compound
near
presenc
gsh
near
presenc
tcep
bmce
similarli
among
hit
compound
lost
inhibitori
activ
presenc
dtt
tcep
hill
slope
valu
compound
near
least
one
reduc
agent
case
plpro
hit
hill
slope
compound
compound
increas
gsh
tcep
compound
compound
still
near
gsh
bmce
although
compound
neg
dtt
may
produc
aggregationbas
inhibit
major
hit
compound
show
dramat
shift
ic
valu
produc
aggregationbas
inhibit
accord
analysi
dtt
gener
appear
prevent
aggregationbas
nonspecif
inhibit
major
neg
therefor
data
demonstr
inhibitori
activ
compound
screen
serin
cystein
proteas
greatli
affect
reduc
agent
use
assay
final
studi
stabil
gsh
assay
buffer
ic
valu
comparison
reveal
reduc
agent
significantli
affect
inhibitori
activ
screen
compound
lead
import
question
ic
valu
consid
true
indic
potenc
inhibitor
suggest
ic
valu
gsh
consid
best
indic
vivo
efficaci
least
intracellular
enzym
target
gsh
physiolog
reduc
agent
human
bodi
howev
gsh
use
reduc
agent
ht
assay
due
concern
potenti
oxid
assay
condit
gsh
known
undergo
oxid
aqueou
buffer
condit
form
disulfid
bond
gssg
carri
detail
studi
stabil
gsh
monitor
gsh
gssg
amount
found
gsh
oxid
gssg
time
period
room
temperatur
presenc
assay
buffer
affect
stabil
gsh
fig
wherea
gsh
slightli
stabil
two
cystein
proteas
plpro
compar
gsh
alon
fig
thu
feasibl
use
gsh
reduc
agent
ht
assay
time
period
provid
fresh
gsh
ad
assay
buffer
everi
h
ht
produc
fals
posit
fals
neg
although
former
elimin
secondari
tertiari
assay
time
effort
fals
neg
initi
ht
assay
derail
effort
drug
discoveri
loss
potenti
novel
inhibitor
result
suggest
reduc
agent
could
differ
effect
substrat
affin
enzym
activ
case
cystein
serin
proteas
enzym
effici
plpro
affect
type
reduc
agent
wherea
effici
affect
plpro
contain
cystein
residu
activ
site
reduc
agent
differ
effect
kinet
paramet
type
reduc
agent
affect
three
proteas
differ
way
observ
keep
presum
role
reduc
agent
antioxid
suggest
reduc
agent
may
addit
function
work
simpl
antioxid
recent
studi
show
dtt
weaken
monom
interac
note
compound
inhibit
lm
concentr
consid
posit
hit
compound
reduc
agent
posit
gsh
consid
true
posit
hit
target
enzym
addit
role
reduc
agent
remain
discov
result
show
strong
weak
reduc
agent
produc
fals
posit
fals
neg
therefor
case
potenti
risk
miss
posit
hit
compound
could
lead
novel
inhibitor
although
remain
determin
exactli
reduc
agent
affect
appar
activ
import
note
outcom
ht
assay
serious
affect
choic
reduc
agent
addit
pursu
lead
compound
research
reli
ic
valu
inhibitor
indic
compound
potenc
also
would
problemat
differ
reduc
agent
could
alter
potenc
screen
compound
discov
potenc
inhibitor
alter
approxim
lm
one
reduc
agent
complet
loss
inhibitori
activ
ic
lm
anoth
signific
differ
henc
choic
proper
reduc
agent
critic
may
lead
pursuit
poor
lead
compound
fals
posit
miss
good
potenti
lead
candid
fals
neg
therefor
perform
ht
run
import
awar
effect
differ
reduc
agent
enzym
system
order
pick
right
condit
specif
ht
run
suggest
use
gsh
rather
commonli
use
nonphysiolog
reduc
agent
gsh
use
certain
assay
perform
test
set
assay
small
number
compound
includ
known
inhibitor
variou
reduc
agent
may
use
identifi
nonphysiolog
reduc
agent
could
detect
largest
number
known
inhibitor
simpl
experi
could
significantli
improv
qualiti
follow
ht
